SCHEMBL8713892

SCHEMBL8713892

CCNc1cccnc1N1CCN(C(=O)c2ccc(C(=O)N(CC)CCO)cc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.44
SLC6A7 Q99884 7/20 0.41
HSD11B1 P28845 1/20 0.41
KDM4E B2RXH2 1/20 0.39
ACACB O00763 1/20 0.39
ACACA Q13085 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ALDH1A1 P00352 2/20 0.38
TSHR P16473 1/20 0.38
GPR6 P46095 1/20 0.38
OPRD1 P41143 1/20 0.38
CHIA Q9BZP6 1/20 0.38
DCTPP1 Q9H773 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8714440 0.89 ADRA2A (0.46) SLC6A7HSD11B1KDM4EACACBACACA
SCHEMBL8709493 0.83 ALDH1A1 (0.48) PARP1SLC6A7HSD11B1KDM4EL3MBTL1
SCHEMBL8709483 0.83 HSD11B1 (0.51) PARP1SLC6A7HSD11B1KDM4EL3MBTL1
SCHEMBL8711563 0.83 ADRA2A (0.45) SLC6A7HSD11B1KDM4EL3MBTL1ALDH1A1
SCHEMBL8711077 0.82 OPRM1 (0.51) SLC6A7HSD11B1KDM4EACACBACACA
SCHEMBL8713901 0.81 ADRA2A (0.46) SLC6A7HSD11B1KDM4EACACBACACA
SCHEMBL8707737 0.81 ADRA2A (0.44) SLC6A7HSD11B1KDM4EL3MBTL1ALDH1A1
SCHEMBL8712141 0.81 ADRA2A (0.45) SLC6A7HSD11B1KDM4EACACBACACA
SCHEMBL9689915 0.80 SLC6A7 (0.59) SLC6A7KDM4EALDH1A1DCTPP1SMN1; SMN2
SCHEMBL7869792 0.80 ADRA2A (0.43) SLC6A7HSD11B1KDM4EACACBACACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1998054140-A1 NOVEL TEREPHTHALAMIDE DERIVATIVES DONGWHA PHARMACEUTICAL IND. CO., LTD. (KR) 1998-12-03 WO disclosed